STEPHANIE AMBER TRAYLOR

Allopathic & Osteopathic Physicians|General Practice COLUMBUS, OH NPI 1306227426

General Payments — all program years on this page

$57,927.22

  • Category: General Payments
  • Program years: PY2019–2024
  • Record count: 40
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $32,979.15 across 18 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $32,979.1518

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $32,979.1518

By program year

Program yearAmountRecords
2019 $38.633
2020 $15.291
2022 $6,795.876
2023 $18,098.2812
2024 $32,979.1518

Records — PY2024 (18)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1137689008 Takeda Pharmaceuticals U.S.A., Inc. $2,253.33 01/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137689010 Takeda Pharmaceuticals U.S.A., Inc. $2,253.33 02/14/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137689012 Takeda Pharmaceuticals U.S.A., Inc. $2,253.33 03/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137689014 Takeda Pharmaceuticals U.S.A., Inc. $2,253.33 04/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137689016 Takeda Pharmaceuticals U.S.A., Inc. $2,253.33 05/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137689018 Takeda Pharmaceuticals U.S.A., Inc. $2,253.33 06/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137689020 Takeda Pharmaceuticals U.S.A., Inc. $2,253.33 07/12/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137689022 Takeda Pharmaceuticals U.S.A., Inc. $2,253.33 08/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137689024 Takeda Pharmaceuticals U.S.A., Inc. $2,353.33 09/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137689026 Takeda Pharmaceuticals U.S.A., Inc. $281.67 09/18/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137689028 Takeda Pharmaceuticals U.S.A., Inc. $882.50 09/18/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137689030 Takeda Pharmaceuticals U.S.A., Inc. $845.01 09/18/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137689032 Takeda Pharmaceuticals U.S.A., Inc. $2,353.33 10/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137689034 Takeda Pharmaceuticals U.S.A., Inc. $1,176.67 10/25/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137689036 Takeda Pharmaceuticals U.S.A., Inc. $2,353.33 11/13/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137689038 Takeda Pharmaceuticals U.S.A., Inc. $1,176.67 11/20/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137689040 Takeda Pharmaceuticals U.S.A., Inc. $2,353.33 12/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137689042 Takeda Pharmaceuticals U.S.A., Inc. $1,176.67 12/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.